Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRAN Alterity Therapeutics (PRAN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrends About Alterity Therapeutics Stock (NASDAQ:PRAN) 30 days 90 days 365 days Advanced Chart Ad Stansberry ResearchWhat do “they” know that you don’t?Over the past decade, the Central Bank trade has been clear: Sell Treasuries, buy gold. In fact, Central Banks have now DOUBLED their gold stake - sending stockpiles to the highest level since the '90s, according to The Kobeissi Letter.No. 1 way to profit from gold's rise, and you can get started for less than $10. Get Alterity Therapeutics alerts:Sign Up Key Stats Today's Range$1.07▼$1.1050-Day Range$0.95▼$2.0652-Week Range$1.09▼$2.91Volume9,597 shsAverage Volume130,956 shsMarket Capitalization$9.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAlterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.Read More… What do “they” know that you don’t? (Ad)Over the past decade, the Central Bank trade has been clear: Sell Treasuries, buy gold. In fact, Central Banks have now DOUBLED their gold stake - sending stockpiles to the highest level since the '90s, according to The Kobeissi Letter.No. 1 way to profit from gold's rise, and you can get started for less than $10. Receive PRAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRAN Stock News HeadlinesAlterity Therapeutics Advances in Neurodegenerative Drug TrialsNovember 21 at 10:22 PM | markets.businessinsider.comAlterity Therapeutics Appoints New Company SecretaryNovember 19 at 2:22 PM | markets.businessinsider.comWhat do “they” know that you don’t?Over the past decade, the Central Bank trade has been clear: Sell Treasuries, buy gold. In fact, Central Banks have now DOUBLED their gold stake - sending stockpiles to the highest level since the '90s, according to The Kobeissi Letter.November 22, 2024 | Stansberry Research (Ad)Alterity Therapeutics appoints Abby Macnish Niven as secretaryNovember 19 at 2:22 PM | markets.businessinsider.comAlterity Therapeutics Unveils New Advances for MSA TrackingNovember 12, 2024 | markets.businessinsider.comAlterity Therapeutics announces new publication on ATH434November 6, 2024 | markets.businessinsider.comAlterity Therapeutics: Innovative Approach with ATH434November 6, 2024 | markets.businessinsider.comAlterity Therapeutics Reveals Positive MSA Trial DataOctober 31, 2024 | markets.businessinsider.comSee More Headlines PRAN Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Alterity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include Meta Platforms (META), Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Intercept Pharmaceuticals (ICPT), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA) and Conatus Pharmaceuticals (CNAT). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PRAN CUSIPN/A CIK1131343 Webwww.pranabio.com Phone(139) 349-4906FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.37 Quick RatioN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales63.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book0.76Miscellaneous Outstanding Shares8,900,000Free FloatN/AMarket Cap$9.52 million OptionableNot Optionable Beta1.05 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:PRAN) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRAN Stock Alerts